Table of Contents

The Political Economy of HIV/AIDS in Developing Countries

The Political Economy of HIV/AIDS in Developing Countries

TRIPS, Public Health Systems and Free Access

Edited by Benjamin Coriat

The book is based on original data and field studies from Brazil, Thailand, India and Sub-Saharan Africa. Focusing on the issue of universal and free access to treatment (a goal now taken to heart by the international community), it assesses the progress made and presents a rigorous diagnosis of the obstacles that remain, especially the constraints imposed by TRIPS and the poor state of most public health systems in Southern countries. In so doing, the book renews our understanding of the political economy of HIV/AIDS in these vast regions, where it continues to spread with devastating social and economic consequences.

Chapter 2: New Trends in IP Protection and Health Issues in FTA Negotiations

Gaëlle Krikorian

Subjects: development studies, development economics, law and development, economics and finance, development economics, health policy and economics, international economics, political economy, law - academic, law and development, politics and public policy, political economy, social policy and sociology, health policy and economics


Gaëlle Krikorian INTRODUCTION Countries signing free trade agreements (FTAs) are led to adopt more restrictive intellectual property (IP) standards than required by the World Trade Organization’s (WTO) agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) and to relinquish some of the latter’s major flexibilities. The increase in protection includes expansion of patentability criteria, extension of term of patent protection, creation of exclusive rights on marketing approval data, limitation of compulsory licensing use and parallel import, and creation of linkage between patent status and drug marketing approval. Since these measures either institute new monopolies or strengthen existing ones, they typically have an impact on access to medicine. As more and more countries negotiate and sign bilateral or regional agreements, the list of nations adopting such standards continues to grow. At a time when reliance on generic medicine is more imperative than ever, it may seem surprising to see governments adopt trade policies inconsistent with their declared health policies and the needs of their populations. In order to understand the position of the governments as far as health and trade are concerned, we need to look closely at the way these bilateral negotiations unfold and the role played by the various actors – namely, the negotiators formally involved in the process, the industries involved informally, and the civil society largely involved despite the will of the political leaders. The bilateral negotiations central to this analysis follow several recent events of great importance in the history of health and intellectual property:...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information